In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.

PubWeight™: 2.44‹?› | Rank: Top 2%

🔗 View Article (PMID 16424222)

Published in J Immunol on February 01, 2006


Gamze Piskin1, Regien M R Sylva-Steenland, Jan D Bos, Marcel B M Teunissen

Author Affiliations

1: Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Articles citing this

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56

Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med (2008) 5.25

Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol (2009) 4.73

Th17 cells in human disease. Immunol Rev (2008) 4.27

Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity (2011) 3.75

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68

Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol (2009) 2.31

Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20

Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol (2009) 1.94

Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol (2009) 1.91

Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol (2009) 1.90

IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev (2010) 1.76

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep (2007) 1.69

CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest (2009) 1.65

Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest (2006) 1.65

From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev (2008) 1.65

Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61

Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest (2012) 1.58

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol (2012) 1.46

T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol (2008) 1.46

Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther (2009) 1.28

New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol (2012) 1.21

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol (2008) 1.18

Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm (2009) 1.17

Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol (2014) 1.16

TLR3 drives IRF6-dependent IL-23p19 expression and p19/EBI3 heterodimer formation in keratinocytes. Immunol Cell Biol (2015) 1.11

Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One (2013) 1.07

Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology (2012) 1.07

Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol (2012) 1.06

Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr (2009) 1.04

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs (2014) 1.00

Current concepts in the pathogenesis of psoriasis. Indian J Dermatol (2009) 0.98

Cytokines in psoriasis. Cytokine (2015) 0.98

Inflammasome activation of IL-1 family mediators in response to cutaneous photodamage. Photochem Photobiol (2012) 0.97

The pro-inflammatory role of TGFβ1: a paradox? Int J Biol Sci (2012) 0.97

NK cells and psoriasis. J Biomed Biotechnol (2011) 0.97

The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol (2014) 0.96

Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma. PLoS One (2012) 0.96

Current perspectives on the role of IL-17 in autoimmune disease. J Inflamm Res (2010) 0.96

IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95

Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol (2015) 0.95

The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep (2010) 0.92

Lithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2). J Cell Physiol (2012) 0.92

Serum levels of selected Th17 and Th22 cytokines in psoriatic patients. Dis Markers (2013) 0.91

Ustekinumab: differential use in psoriasis. Clin Cosmet Investig Dermatol (2011) 0.91

Keratinocytes under Fire of Proinflammatory Cytokines: Bona Fide Innate Immune Cells Involved in the Physiopathology of Chronic Atopic Dermatitis and Psoriasis. J Allergy (Cairo) (2012) 0.91

Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol Med (2014) 0.89

Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol (2011) 0.88

IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDS. J Neuroimmune Pharmacol (2011) 0.88

CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets (2010) 0.88

Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol (2015) 0.88

Genetic Epidemiology of Psoriasis. Curr Dermatol Rep (2014) 0.87

Role of TH-17 cells in rheumatic and other autoimmune diseases. Rheumatology (Sunnyvale) (2011) 0.86

Harnessing dendritic cells in inflammatory skin diseases. Semin Immunol (2011) 0.86

Sarcoptes scabiei mites modulate gene expression in human skin equivalents. PLoS One (2013) 0.85

Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus. Mediators Inflamm (2014) 0.84

Intestinal intraepithelial lymphocyte-enterocyte crosstalk regulates production of bactericidal angiogenin 4 by Paneth cells upon microbial challenge. PLoS One (2013) 0.83

The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights (2014) 0.83

Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer. J Biomed Biotechnol (2012) 0.82

Epidermal phospholipase Cδ1 regulates granulocyte counts and systemic interleukin-17 levels in mice. Nat Commun (2012) 0.82

Muramyl dipeptide induces Th17 polarization through activation of endothelial cells. J Immunol (2011) 0.82

IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice. PLoS One (2013) 0.81

Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci (2010) 0.81

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther (2011) 0.81

Evaluation of Chosen Cytokine Levels among Patients with Herpes Zoster as Ability to Provide Immune Response. PLoS One (2016) 0.81

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells. Mucosal Immunol (2014) 0.80

A role for RUNX3 in inflammation-induced expression of IL23A in gastric epithelial cells. Cell Rep (2014) 0.80

Platelet-activating factor induces Th17 cell differentiation. Mediators Inflamm (2011) 0.80

Candidate EDA targets revealed by expression profiling of primary keratinocytes from Tabby mutant mice. Gene (2008) 0.79

Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. Arch Dermatol Res (2012) 0.79

Immunobiologics in the treatment of psoriasis. Clin Immunol (2007) 0.79

Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells. Eur J Immunol (2012) 0.79

Immunomodulatory effects of balneotherapy with hae-un-dae thermal water on imiquimod-induced psoriasis-like murine model. Ann Dermatol (2014) 0.78

Inhibition of imiquimod-induced psoriasis-like dermatitis in mice by herbal extracts from some Indian medicinal plants. Protoplasma (2015) 0.77

IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization. J Exp Med (2016) 0.76

RAC1 activation drives pathologic interactions between the epidermis and immune cells. J Clin Invest (2016) 0.75

The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis. J Clin Aesthet Dermatol (2016) 0.75

RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease. EMBO Mol Med (2017) 0.75

Defects in dermal Vγ4 γ δ T cells result in delayed wound healing in diabetic mice. Am J Transl Res (2016) 0.75

IL-12 protects from psoriasiform skin inflammation. Nat Commun (2016) 0.75

Emerging therapies for the treatment of psoriasis. Dermatol Ther (Heidelb) (2012) 0.75

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag (2010) 0.75

Plasma Levels of Interleukin-17, Interleukin-23, and Transforming Growth Factor-β in Sudanese Patients with Vitiligo: A Case-Control Study. Indian J Dermatol (2015) 0.75

Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells. Oncotarget (2016) 0.75

In situ expression of (R)-carbonyl reductase rebalancing an asymmetric pathway improves stereoconversion efficiency of racemic mixture to (S)-phenyl-1,2-ethanediol in Candida parapsilosis CCTCC M203011. Microb Cell Fact (2016) 0.75

Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother (2014) 0.75

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. Clin Cosmet Investig Dermatol (2009) 0.75

CD19+ B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity. Braz J Med Biol Res (2016) 0.75

Thymic stromal lymphopoietin-induced interleukin-17A is involved in the development of IgE-mediated atopic dermatitis-like skin lesions in mice. Immunology (2015) 0.75

Articles by these authors

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol (2011) 1.62

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol (2007) 1.30

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem (2007) 1.10

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

Overview of psoriasis. Dermatol Ther (2004) 1.04

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95

Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses. J Immunol (2011) 0.93

Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine (2012) 0.92

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91

Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.90

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89

Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res (2009) 0.89

T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89

Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Etanercept: an overview of dermatologic adverse events. Arch Dermatol (2011) 0.87

Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87

The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86

Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86

Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85

Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83

Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med (2010) 0.82

Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat (2011) 0.82

Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol (2008) 0.82

Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol (2006) 0.82

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82

Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol (2008) 0.82

Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res (2004) 0.82

Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis (2013) 0.82

Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol (2005) 0.81

Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol (2003) 0.81

Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells. Hum Vaccin Immunother (2013) 0.81

Tertiary teledermatology: a systematic review. Telemed J E Health (2010) 0.80

In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol (2004) 0.80

Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol (2002) 0.80

Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.79

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79

Lichen planus remission is associated with a decrease of human herpes virus type 7 protein expression in plasmacytoid dendritic cells. Arch Dermatol Res (2007) 0.79

Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol (2004) 0.79

Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol (2009) 0.79

Epidermal cis-urocanic acid levels correlate with lower specific cellular immune responses after hepatitis B vaccination of ultraviolet B-exposed humans. Photochem Photobiol (2003) 0.78

Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol (2010) 0.78

Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol (2008) 0.77

Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol (2006) 0.77

UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. Photochem Photobiol (2002) 0.77

Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol (2004) 0.77

Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol (2004) 0.77

Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat (2007) 0.76

The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol (2004) 0.76

Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study. Contact Dermatitis (2013) 0.76

A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology (2012) 0.76

Smallpox: what the dermatologist should know. Skinmed (2004) 0.76

Proliferating prevalence of concepts and controversies in atopic eczema. J Cosmet Dermatol (2004) 0.75

The atopic epidemic and the humidity hypothesis. J Cosmet Dermatol (2004) 0.75

The use of patch tests in determining hypersensitivity to etanercept and infliximab. Arch Dermatol (2008) 0.75

Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Exp Dermatol (2010) 0.75